|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Capitanio U, Bensalah K, Bex A, Boorjian
SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P:
Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fisher R, Gore M and Larkin J: Current and
future systemic treatments for renal cell carcinoma. Semin Cancer
Biol. 23:38–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Climent MA, Munoz-Langa J,
Basterretxea-Badiola L and Santander-Lobera C: Systematic review
and survival meta-analysis of real world evidence on first-line
pazopanib for metastatic renal cell carcinoma. Crit Rev Oncol
Hematol. 121:45–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Candido J and Hagemann T: Cancer-related
inflammation. J Clin Immunol. 33 (Suppl 1):S79–S84. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Swann JB and Smyth MJ: Immune surveillance
of tumors. J Clin Invest. 117:1137–1146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thompson RH, Dong H, Lohse CM, Leibovich
BC, Blute ML, Cheville JC and Kwon ED: PD-1 is expressed by
tumor-infiltrating immune cells and is associated with poor outcome
for patients with renal cell carcinoma. Clin Cancer Res.
13:1757–1761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vogelzang NJ, Priest ER and Borden L:
Spontaneous regression of histologically proved pulmonary
metastases from renal cell carcinoma: A case with 5-year followup.
J Urol. 148:1247–1248. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Janiszewska AD, Poletajew S and
Wasiutynski A: Spontaneous regression of renal cell carcinoma.
Contemp Oncol (Pozn). 17:123–127. 2013.PubMed/NCBI
|
|
11
|
Considine B and Hurwitz ME: Current status
and future directions of immunotherapy in renal cell carcinoma.
Curr Oncol Rep. 21:342019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Escudier B: Emerging immunotherapies for
renal cell carcinoma. Ann Oncol. 23 (Suppl 8):viii35–viii40. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Amin A, Dudek AZ, Logan TF, Lance RS,
Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh
LI, et al: Survival with AGS-003, an autologous dendritic
cell-based immunotherapy, in combination with sunitinib in
unfavorable risk patients with advanced renal cell carcinoma (RCC):
Phase 2 study results. J Immunother Cancer. 3:142015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bingle L, Brown NJ and Lewis CE: The role
of tumour-associated macrophages in tumour progression:
Implications for new anticancer therapies. J Pathol. 196:254–265.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fridman WH, Pages F, Sautes-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schraml P, Athelogou M, Hermanns T, Huss R
and Moch H: Specific immune cell and lymphatic vessel signatures
identified by image analysis in renal cancer. Mod Pathol.
32:1042–1052. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liss MA, Chen Y, Rodriguez R, Pruthi D,
Johnson-Pais T, Wang H, Mansour A and Kaushik D: Immunogenic
heterogeneity of renal cell carcinoma with venous tumor thrombus.
Urology. 124:168–173. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rohr-Udilova N, Klinglmuller F,
Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F,
Timelthaler G, Oberhuber G, Pinter M, et al: Deviations of the
immune cell landscape between healthy liver and hepatocellular
carcinoma. Sci Rep. 8:62202018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei L, Jin Z, Yang S, Xu Y, Zhu Y and Ji
Y: TCGA-assembler 2: Software pipeline for retrieval and processing
of TCGA/CPTAC data. Bioinformatics. 34:1615–1617. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Smyth GK: Limma: Linear models for
microarray dataBioinformatics and Computational Biology Solutions
Using R and Bioconductor. Gentleman R, Carey VJ, Huber W, Irizarry
RA and Dudoit S: Statistics for Biology and Health Springer New
York; New York, NY: pp. 397–420. 2005, View Article : Google Scholar
|
|
22
|
Peltanova B, Raudenska M and Masarik M:
Effect of tumor microenvironment on pathogenesis of the head and
neck squamous cell carcinoma: A systematic review. Mol Cancer.
18:632019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Senbabaoglu Y, Gejman RS, Winer AG, Liu M,
Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A,
et al: Tumor immune microenvironment characterization in clear cell
renal cell carcinoma identifies prognostic and
immunotherapeutically relevant messenger RNA signatures. Genome
Biol. 17:2312016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bremnes RM, Al-Shibli K, Donnem T, Sirera
R, Al-Saad S, Andersen S, Stenvold H, Camps C and Busund LT: The
role of tumor-infiltrating immune cells and chronic inflammation at
the tumor site on cancer development, progression, and prognosis:
Emphasis on non-small cell lung cancer. J Thorac Oncol. 6:824–833.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishigami S, Natsugoe S, Tokuda K, Nakajo
A, Che X, Iwashige H, Aridome K, Hokita S and Aikou T: Prognostic
value of intratumoral natural killer cells in gastric carcinoma.
Cancer. 88:577–583. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ribatti D, Ennas MG, Vacca A, Ferreli F,
Nico B, Orru S and Sirigu P: Tumor vascularity and
tryptase-positive mast cells correlate with a poor prognosis in
melanoma. Eur J Clin Invest. 33:420–425. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
de Visser KE, Eichten A and Coussens LM:
Paradoxical roles of the immune system during cancer development.
Nat Rev Cancer. 6:24–37. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yao J, Xi W, Zhu Y, Wang H, Hu X and Guo
J: Checkpoint molecule PD-1-assisted CD8+ T lymphocyte
count in tumor microenvironment predicts overall survival of
patients with metastatic renal cell carcinoma treated with tyrosine
kinase inhibitors. Cancer Manag Res. 10:3419–3431. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lahl K, Loddenkemper C, Drouin C, Freyer
J, Arnason J, Eberl G, Hamann A, Wagner H, Huehn J and Sparwasser
T: Selective depletion of Foxp3+ regulatory T cells
induces a scurfy-like disease. J Exp Med. 204:57–63. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sakaguchi S, Miyara M, Costantino CM and
Hafler DA: FOXP3+ regulatory T cells in the human immune
system. Nat Rev Immunol. 10:490–500. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shang B and Liu Y, Jiang SJ and Liu Y:
Prognostic value of tumor-infiltrating FoxP3+ regulatory
T cells in cancers: A systematic review and meta-analysis. Sci Rep.
5:151792015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Griffiths RW, Elkord E, Gilham DE, Ramani
V, Clarke N, Stern PL and Hawkins RE: Frequency of regulatory T
cells in renal cell carcinoma patients and investigation of
correlation with survival. Cancer Immunol Immunother. 56:1743–1753.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Finke JH, Rini B, Ireland J, Rayman P,
Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R and
Bukowski R: Sunitinib reverses type-1 immune suppression and
decreases T-regulatory cells in renal cell carcinoma patients. Clin
Cancer Res. 14:6674–6682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Papaioannou E, Sakellakis M, Melachrinou
M, Tzoracoleftherakis E, Kalofonos H and Kourea E: A Standardized
Evaluation Method for FOXP3+ Tregs and CD8+
T-cells in breast carcinoma: Association with breast carcinoma
subtypes, stage and prognosis. Anticancer Res. 39:1217–1232. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Seminerio I, Descamps G, Dupont S, de
Marrez L, Laigle JA, Lechien JR, Kindt N, Journe F and Saussez S:
Infiltration of FoxP3+ regulatory T cells is a strong
and independent prognostic factor in head and neck squamous cell
carcinoma. Cancers (Basel). 11(pii): E2272019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van Furth R and Cohn ZA: The origin and
kinetics of mononuclear phagocytes. J Exp Med. 128:415–435. 1968.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ziegler-Heitbrock L, Ancuta P, Crowe S,
Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph
GJ, et al: Nomenclature of monocytes and dendritic cells in blood.
Blood. 116:e74–e80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gui T, Shimokado A, Sun Y, Akasaka T and
Muragaki Y: Diverse roles of macrophages in atherosclerosis: From
inflammatory biology to biomarker discovery. Mediators Inflamm.
2012:6930832012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee HW, Choi HJ, Ha SJ, Lee KT and Kwon
YG: Recruitment of monocytes/macrophages in different tumor
microenvironments. Biochim Biophys Acta. 1835:170–179.
2013.PubMed/NCBI
|
|
40
|
Movahedi K, Laoui D, Gysemans C, Baeten M,
Stangé G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De
Baetselier P and Van Ginderachter JA: Different tumor
microenvironments contain functionally distinct subsets of
macrophages derived from Ly6C(high) monocytes. Cancer Res.
70:5728–5739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization: Tumor-associated macrophages
as a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Romano E, Kusio-Kobialka M, Foukas PG,
Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero
P and Speiser DE: Ipilimumab-dependent cell-mediated cytotoxicity
of regulatory T cells ex vivo by nonclassical monocytes in melanoma
patients. Proc Natl Acad Sci USA. 112:6140–6145. 2015. View Article : Google Scholar : PubMed/NCBI
|
